During his research career on check-point blockade, Prof. James P. Allison utilized IFN-γ ELISpot assays numerous times to characterize the function of antigen-specific T cells before and after anti-CTLA-4 treatment. On at least three occasions, regardless if the study was on human subjects or conducted as mouse models, the research group chose ELISpot kits from Mabtech.
Today, James P. Allison will, together with Prof. Tasuku Honjo, be awarded the Nobel Prize for their work. We are very proud to have been a tiny part of the studies leading up to their amazing findings.
Prof. James P. Allison
- Gregor et al., CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004
- Kitano et al., Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunol Res. 2013
- Gubin et al., Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens. Nature 2014